Header Logo

Connection

HANA EL SAHLY to Adolescent

Back to Details
This is a "connection" page, showing publications HANA EL SAHLY has written about Adolescent.
HANA EL SAHLY
Connection Strength
0.416
Adolescent
  1. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785.
    View in: PubMed
    Score: 0.050
  2. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
    View in: PubMed
    Score: 0.025
  3. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
    View in: PubMed
    Score: 0.023
  4. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
    View in: PubMed
    Score: 0.021
  5. A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults. J Infect Dis. 2026 Mar 17; 233(3):e641-e645.
    View in: PubMed
    Score: 0.017
  6. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2026 Jan 01; 69:127959.
    View in: PubMed
    Score: 0.017
  7. Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
    View in: PubMed
    Score: 0.016
  8. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
    View in: PubMed
    Score: 0.016
  9. Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1159.
    View in: PubMed
    Score: 0.015
  10. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
    View in: PubMed
    Score: 0.015
  11. Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 07 03; 6(7):e2323349.
    View in: PubMed
    Score: 0.014
  12. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection. J Infect Dis. 2023 05 29; 227(11):1303-1312.
    View in: PubMed
    Score: 0.014
  13. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clin Infect Dis. 2023 01 13; 76(2):271-280.
    View in: PubMed
    Score: 0.014
  14. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002 Oct 01; 35(7):802-7.
    View in: PubMed
    Score: 0.013
  15. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
    View in: PubMed
    Score: 0.013
  16. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
    View in: PubMed
    Score: 0.013
  17. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
    View in: PubMed
    Score: 0.012
  18. Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis. 2001 Feb 01; 183(3):461-8.
    View in: PubMed
    Score: 0.012
  19. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.011
  20. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
    View in: PubMed
    Score: 0.009
  21. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.009
  22. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017 02 07; 35(6):923-928.
    View in: PubMed
    Score: 0.009
  23. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.008
  24. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.008
  25. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93.
    View in: PubMed
    Score: 0.008
  26. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.007
  27. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.007
  28. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13; 29(44):7733-9.
    View in: PubMed
    Score: 0.006
  29. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
    View in: PubMed
    Score: 0.006
  30. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.005
  31. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.